Geopolitics Alpha

Market closed · last trade · ETF proxies, Alpaca IEX

Jazz Pharmaceuticals CEO Touts Ziihera Launch, Pipeline After Raising Revenue Guidance

Published . Updated .

Key takeaways

  • Jazz Pharmaceuticals (NASDAQ:JAZZ) is counting on new drug launches, pipeline studies and acquisitions to sustain growth across its sleep, epilepsy and oncology businesses, President and CEO Renee Gala said at an investor event.
  • Exposed: JAZZ, LLY, JNJ, PFE, MRK
  • Market reaction: price tracking starts with the next trading session.

Market Call

Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.

Get these market calls by email

The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.

Free. We only use your email to send the digest and never sell or share it. See our privacy policy.

Jazz Pharmaceuticals CEO Touts Ziihera Launch, Pipeline After Raising Revenue Guidance

Jazz Pharmaceuticals (NASDAQ:JAZZ) is counting on new drug launches, pipeline studies and acquisitions to sustain growth across its sleep, epilepsy and oncology businesses, President and CEO Renee Gala said at an investor event. Gala pointed to third-quarter revenue of $1.24

Directly affected

  • JAZZ Jazz Pharmaceuticals+10.1% 30d

    Named in this report.

Indirectly affected

  • XLV Health Care Select Sector SPDR

    Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story.

  • XBI SPDR S&P Biotech ETF

    SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story.

  • LLY Eli Lilly and+25.0% 30d

    Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.

  • JNJ Johnson & Johnson+12.1% 30d

    Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.

  • PFE Pfizer+5.2% 30d

    Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.

  • MRK Merck+3.5% 30d

    Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.

Price reaction, T-5 to T+3

TickerT-5T-3T-1T0T+1T+2T+3
JAZZ+4.14%+7.59%baseafter closeafter closeafter closeafter close
XLV+5.96%+2.17%baseafter closeafter closeafter closeafter close
XBI+4.00%+3.40%baseafter closeafter closeafter closeafter close
LLY+6.37%+2.56%baseafter closeafter closeafter closeafter close
JNJ+4.35%+0.70%baseafter closeafter closeafter closeafter close
PFE+5.31%+2.32%baseafter closeafter closeafter closeafter close
MRK+8.11%+3.06%baseafter closeafter closeafter closeafter close

Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.

Jazz Pharmaceuticals CEO Touts Ziihera Launch, Pipeline After Raising Revenue Guidance Yahoo Finance

Source: Yahoo Finance

Select Sector Spdr Tr (XLV) since this story, compared with the market

CompanyWhenMoveStatus
JAZZthree days earlier+7.59%final price
JAZZfive days earlier+4.14%final price
Johnson & Johnson (JNJ)three days earlier+0.70%final price
Johnson & Johnson (JNJ)five days earlier+4.35%final price
Eli Lilly (LLY)three days earlier+2.56%final price
Eli Lilly (LLY)five days earlier+6.37%final price
Merck (MRK)three days earlier+3.06%final price
Merck (MRK)five days earlier+8.11%final price
Pfizer (PFE)three days earlier+2.32%final price
Pfizer (PFE)five days earlier+5.31%final price
Spdr Series Trust (XBI)three days earlier+3.40%final price
Spdr Series Trust (XBI)five days earlier+4.00%final price
Select Sector Spdr Tr (XLV)three days earlier+2.17%final price
Select Sector Spdr Tr (XLV)five days earlier+5.96%final price

Trades by members of Congress and officials in the stocks in this story

Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).

Who gains and who loses around Select Sector Spdr Tr (XLV)

Companies tied to this story

  • XLV Select Sector Spdr Tr

    Select Sector Spdr Tr (XLV) is linked, with no stored direction, medium confidence in the 21 Nov 2026 story “Jazz Pharmaceuticals CEO Touts Ziihera Launch, Pipeline After Raising Revenue Guidance.” Reason on file: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story

  • XBI Spdr Series Trust

    In “Jazz Pharmaceuticals CEO Touts Ziihera Launch, Pipeline After Raising Revenue Guidance,” Spdr Series Trust (XBI) is linked, with no stored direction, medium confidence. Reason on file: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story

  • LLY Eli Lilly

    In “Jazz Pharmaceuticals CEO Touts Ziihera Launch, Pipeline After Raising Revenue Guidance,” Eli Lilly (LLY) is linked, with no stored direction, medium confidence. Reason on file: Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story

  • JNJ Johnson & Johnson

    In “Jazz Pharmaceuticals CEO Touts Ziihera Launch, Pipeline After Raising Revenue Guidance,” Johnson & Johnson (JNJ) is linked, with no stored direction, medium confidence. Reason on file: Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story

  • PFE Pfizer

    Pfizer (PFE) is linked, with no stored direction, medium confidence in the 21 Nov 2026 story “Jazz Pharmaceuticals CEO Touts Ziihera Launch, Pipeline After Raising Revenue Guidance.” Reason on file: Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story

  • MRK Merck

    In “Jazz Pharmaceuticals CEO Touts Ziihera Launch, Pipeline After Raising Revenue Guidance,” Merck (MRK) is linked, with no stored direction, medium confidence. Reason on file: Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story

Select Sector Spdr Tr (XLV) and the energy link

The 21 Nov 2026 story “Jazz Pharmaceuticals CEO Touts Ziihera Launch, Pipeline After Raising Revenue Guidance” names Select Sector Spdr Tr (XLV) because of Energy.

For Select Sector Spdr Tr (XLV), the reason on file says Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story

Spdr Series Trust (XBI) is here too. Its reason reads: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story

Dates in the story, and the Select Sector Spdr Tr (XLV) price range

LLY traded between 1239.21 and 1458.90 across 20 sessions. The latest close on file is 1430.09.

A simple score for Select Sector Spdr Tr (XLV)

46 out of 100

“Jazz Pharmaceuticals CEO Touts Ziihera Launch, Pipeline After Raising Revenue Guidance” scores 46 out of 100. The score uses 1 source, and 6 linked companies.